- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03914794
En studie av pemigatinib hos ikke-muskelinvasiv blærekreftpasienter med tilbakevendende lav- eller middelsrisikosvulster
Fase 2 Mulighetsstudie av pemigatinib hos ikke-muskelinvasive blærekreftpasienter med tilbakevendende lav- eller middelsrisikosvulster
This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
It is a single-arm phase 2 window of opportunity study to assess the antineoplastic activity of pemigatinib in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Enrolled patients will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT). The primary endpoint will be complete response rate as determined at TURBT. Secondary endpoints will include safety profile, associations between complete response rate and tumor mutation/fusion status (e.g. FGFR3 specifically, others will also be examined) and NMIBC risk group (low- vs. intermediate-risk), and assessment of pemigatinib post-treatment urothelial tissue concentrations. The study will be conducted at 4-5 high volume bladder cancer institutions within the US and managed through the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center clinical research office.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20016
- Sibley Memorial Hospital
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21205
- Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center
-
-
New York
-
Syracuse, New York, Forente stater, 13210
- Associated Medical Professionals Urology
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Forente stater, 19004
- Midlantic Urology
-
Lancaster, Pennsylvania, Forente stater, 17604
- Keystone Urology
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forente stater, 29572
- Carolina Urologic Research Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Prior histologically confirmed low- or intermediate-risk non-muscle invasive urothelial carcinoma of the bladder (NMIBC) defined according to the following characteristics:
-
Low Risk
- Initial tumor with all of the following:
- Solitary tumor
- Ta tumor
- Low-grade
- <3 cm
- No CIS
-
Intermediate Risk
--- All tumors not defined in the two adjacent categories (between the category of low- and high-risk)
-
High Risk
- T1 tumor
- High-grade
- CIS
- Multiple and recurrent and large (>3 cm) Ta low-grade tumors (all conditions must be met for this point on Ta low-grade tumors)
-
-
Documented tumor recurrence as noted in standard of care follow up cystoscopy.
-
ECOG (WHO) performance status 0-2
-
Age ≥ 18 years old
-
Patients must have the following laboratory values:
- White blood cell count (WBC) > 3.0 K/mm3
- Absolute neutrophil count (ANC) ≥ 1.5 K/mm3
- Platelets ≥ 100 K/mm3
- Hemoglobin (Hgb) ≥ 9 g/dL
- Serum total bilirubin: ≤ 1.5 x ULN
- ALT and AST ≤ 3.0 x ULN
- Serum calcium < ULN
- Serum phosphate < ULN
- Serum creatinine ≤ 1.5 x ULN or serum creatinine > 1.5 - 3 x ULN if calculated creatinine clearance (CrCl) is ≥ 30 mL/min using the modified Cockcroft-Gault equation
-
Patients who give a written informed consent obtained according to local guidelines
Exclusion Criteria:
- Patients with concurrent upper urinary tract (i.e. ureter, renal pelvis) non-invasive urothelial carcinoma.
- Patients with high grade urothelial carcinoma on their most recent urine cytology.
- Patients with another active second malignancy other than non-melanoma skin cancers and biochemical relapsed prostate cancer. (Patients that have completed all necessary therapy and are considered to be at less than 30% risk of relapse are not considered to have an active second malignancy and are eligible for enrollment.)
- Patients who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies ≤ 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
- Patients who have received prior selective fibroblast growth factor receptor targeting agents (i.e. pemigatinib, dovitinib, BGJ398, AZD4547, JNJ-42756493, etc.).
- Patients who have had radiotherapy ≤ 4 weeks prior to starting study drug, or who have not recovered from radiotherapy toxicities
- Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury ≤ 4 weeks prior to starting study drug, or patients who have had minor procedures (i.e. TURBT), percutaneous biopsies or placement of vascular access device ≤ 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Treatment: Pemigatinib
Patients will receive pemigatinib for 4 to 6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT). |
Participants will take Pemigatinib once daily on days 1 through 28 of each cycle prior to standard of care TURBT.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete Response Rate of Pemigatinib Therapy
Tidsramme: 6 weeks
|
The number of participants with a complete response to pemigatinib therapy. Tumor complete response is defined as the complete absence of any stage bladder tumor on post-treatment Transurethral Resection of a Bladder Tumor (TURBT) and no evidence of recurrent urothelial carcinoma on post-treatment urine cytology. |
6 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Characterize the Safety Profile of Pemigatinib Therapy
Tidsramme: 4 years
|
Number of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 toxicities |
4 years
|
|
Number of Participants With Complete Response and FGFR3 Mutational Status
Tidsramme: Up to 4 weeks
|
Up to 4 weeks
|
|
|
Number of Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Complete Response
Tidsramme: Up to 4 years
|
Number of participants with complete response rate and baseline NMIBC risk group (low- vs. intermediate-risk) |
Up to 4 years
|
|
Relapse Free Survival (RFS) at 6 Months
Tidsramme: 6 months
|
Relapse-free survival (RFS) is defined as the duration of from the on study date to time of first documented bladder tumor of any stage or grade, progression or death, whichever occurs first. |
6 months
|
|
Relapse Free Survival (RFS) at 12 Months
Tidsramme: 12 months
|
Relapse-free survival (RFS) is defined as the duration of from the on study date to time of first documented bladder tumor of any stage or grade, progression or death, whichever occurs first. |
12 months
|
|
Relapse Free Survival (RFS) at 24 Months
Tidsramme: 24 months
|
Relapse-free survival (RFS) is defined as the duration of from the on study date to time of first documented bladder tumor of any stage or grade, progression or death, whichever occurs first. |
24 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Noah M Hahn, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Urologiske neoplasmer
- Karsinom
- Urinblæresykdommer
- Ikke-muskelinvasive blære-neoplasmer
- Neoplasmer i urinblæren
- Karsinom, overgangscelle
- pemigatinib
Andre studie-ID-numre
- J18158
- IRB00194271 (Annen identifikator: JHM IRB)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .